Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealthSpring Baroreflex Therapy Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy THE801.034

    Baroreflex Stimulation Devices

    Customize your policy alerts

    Sign up for healthspring Policy THE801.034 alerts

    Get alerted when Policy THE801.034 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of baroreflex stimulation therapy using implanted devices for heart failure and other indications. It applies to providers seeking coverage for individuals considered for this therapy.

    Policy Summary
    PayerHealthSpring
    PolicyBaroreflex Stimulation Devices
    Policy CodePolicy THE801.034
    Change TypeNew policy
    Effective DateAug 18, 2026
    Next Review DateN/A
    Key ActionBaroreflex stimulation therapy is considered experimental, investigational, and/or unproven for heart failure despite maximally tolerated guideline-directed medical and device therapy, and for all other indications.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy establishes that FDA-approved baroreflex stimulation therapy is experimental, investigational, and/or unproven for heart failure and all other indications.

    Experimental/unprovenHeart failure coverage status
    Experimental/unprovenOther indications
    ≤35%Left ventricular ejection fraction
    <1600 pg/mlNT-proBNP threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 RCTs
    Randomized controlled trials
    8CPT procedure codes

    Coverage Criteria

    Experimental, investigational, and/or unproven indications

    Baroreflex stimulation therapy is considered experimental, investigational, and/or unproven when either of the following indication groups applies.

    Policy coverage stance

    • Heart failure indication: The individual has heart failure despite the use of maximally tolerated guideline-directed medical and device therapy.

      Baroreflex stimulation therapy is considered experimental, investigational, and/or unproven.

    • Other indications: The therapy is being provided for any indication other than the specified heart failure situation.

      Baroreflex stimulation therapy is considered experimental, investigational, and/or unproven.

    Treatment-resistant heart failure evidence conclusion

    Evidence conclusion

    Evidence conclusion: Baroreflex stimulation demonstrates a favorable safety profile and modest improvements in functional capacity and quality of life, but has not shown significant reductions in heart failure morbidity or mortality compared with guideline-directed medical therapy. The evidence is insufficient to determine that the technology improves the net health outcome.

    Evidence is limited by methodological shortcomings and the need for a rigorously designed sham-controlled study.

    Heart failure

    Considered experimental, investigational, and/or unproven

    Heart failure: Baroreflex stimulation therapy with a device approved by the U.S. Food and Drug Administration is considered experimental, investigational, and/or unproven for individuals with heart failure despite the use of maximally tolerated guideline-directed medical and device therapy.

    The experimental, investigational, and/or unproven classification applies even after maximally tolerated guideline-directed medical and device therapy.

    All other indications

    Considered experimental, investigational, and/or unproven

    Other indications: Baroreflex stimulation therapy is considered experimental, investigational, and/or unproven for all other indications.

    Applies to indications other than heart failure.

    Baroreflex stimulation therapy is considered experimental, investigational, and/or unproven for all indications other than heart failure.

    Coding and Clinical Thresholds

    CPT CodesCPT
    64654
    64655
    64656
    64657
    64658
    64659
    93145
    93146
    Left ventricular ejection fraction
    Threshold≤ 35%
    MeasureLeft ventricular ejection fraction
    Policy contextFDA-approved heart failure indication for patients who remain symptomatic despite guideline-directed medical therapy
    NT-proBNP
    Threshold<1600 pg/ml
    MeasureN-terminal pro-B-type natriuretic peptide (NT-proBNP)
    Policy contextFDA-approved heart failure indication for patients who remain symptomatic despite guideline-directed medical therapy

    Provider Action Required

    Denial Risk

    Heart failure therapy remains unproven

    Baroreflex stimulation therapy with an FDA-approved device is considered experimental, investigational, and/or unproven for individuals with heart failure despite the use of maximally tolerated guideline-directed medical and device therapy. Do not represent maximally tolerated therapy as establishing coverage for the procedure.

    Denial Risk

    Heart failure indication is unproven

    For the heart failure indication, baroreflex stimulation therapy remains considered experimental, investigational, and/or unproven even after maximally tolerated guideline-directed medical and device therapy has been used.

    Denial Risk

    Other indications are unproven

    Baroreflex stimulation therapy is considered experimental, investigational, and/or unproven for all indications other than the specified heart failure situation. Claims for other indications therefore do not meet the policy’s coverage position.

    Background

    Baroreflex stimulation devices are implanted devices that electrically stimulate pressure-sensing baroreceptors in the carotid arteries. Activating the baroreflex inhibits sympathetic nervous system activity and increases parasympathetic activity, producing physiologic effects such as reduced heart rate and blood pressure.

    The therapy has been studied as an alternative treatment for patients with treatment-resistant heart failure; however, the policy considers it experimental, investigational, and/or unproven.

    Definitions and Abbreviations

    Baroreflex stimulation devices
    Device typeImplanted device
    FunctionProvides electrical stimulation of the baroreceptors in the carotid arteries
    Physiologic effectActivation inhibits the sympathetic nervous system and can result in slowed heart rate and lower blood pressure
    Baroreceptors
    LocationWithin the walls of the carotid arteries
    RolePressure sensors
    RegulationParticipate in autonomic regulation of heart rate and blood pressure
    Policy Summary
    PayerHealthSpring
    PolicyBaroreflex Stimulation Devices
    Policy CodePolicy THE801.034
    Change TypeNew policy
    Effective DateAug 18, 2026
    Next Review DateN/A
    Key ActionBaroreflex stimulation therapy is considered experimental, investigational, and/or unproven for heart failure despite maximally tolerated guideline-directed medical and device therapy, and for all other indications.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Action RequiredBackgroundDefinitions and Abbreviations
    Baroreflex activation therapy
    Alternate termBaroreflex stimulation therapy
    Therapy descriptionUses an implanted device to stimulate carotid baroreceptors
    Clinical contextPotential alternative treatment for heart failure
    BAT
    MeaningBaroreflex activation therapy or baroreflex stimulation therapy
    TrialEvaluated in the BeAT-HF trial
    Trial useEvaluated in addition to guideline-directed medical therapy
    GDMT
    MeaningGuideline-directed medical therapy for heart failure
    BeAT-HF comparisonCompared with baroreflex activation therapy plus guideline-directed medical therapy
    Therapy componentsMedical therapy includes medications and devices
    6MHWD
    MeaningSix-minute hall walk distance
    UseFunctional-capacity outcome used to assess effects of interventions intended to improve exercise capacity
    Trial contextUsed as an intermediate endpoint in the BeAT-HF trial
    Heart failure patient-reported outcomes
    KCCQ-12Kansas City Cardiomyopathy Questionnaire-12
    MLHFQMinnesota Living With Heart Failure Questionnaire
    PurposePatient-reported outcome instruments used to assess heart-failure-specific quality of life
    NCT
    MeaningNational clinical trial identifier
    UsageIdentifies clinical trials listed in the ongoing and unpublished trials table
    ExampleNCT01679132